Immunovant(US:IMVT)2023-08-14 14:24Immunovant's Pipeline and Focus - Immunovant is developing targeted therapies for autoimmune diseases driven by harmful IgG autoantibodies[2,17] - The company has approximately $330 million in cash balance as of June 30, 2023[14] - There are 22 indications currently announced or in development across the anti-FcRn class[14,26] Batoclimab Development - Batoclimab is in pivotal Phase 3 trials for Myasthenia Gravis (MG) and Thyroid Eye Disease (TED)[30] - A Phase 2b trial of batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is underway, along with a Phase 2 trial in Graves' Disease[30] - In a Phase 2 trial of batoclimab in MG, subjects experienced -59% to -76% change in total IgG from baseline and -54% to -87% change in Anti-AChR-IgG from baseline at week 7, depending on the dose[50,235] IMVT-1402 Development - IMVT-1402, another product candidate, is in Phase 1 development for autoimmune diseases[30] - Preclinical data in monkeys showed that at comparable doses, IgG lowering is similar for both batoclimab and IMVT-1402[177] Market Opportunities - In Myasthenia Gravis, approximately 65,000 patients are estimated in the US and approximately 100,000 in Europe[35] - In Thyroid Eye Disease, 1/3 of the 15,000-20,000 US patients with active, moderate-to-severe TED annually have less severe disease that may benefit from batoclimab[55] - CIDP represents 22% of the total IVIg market by volume[121]